Company / Cash & Equivalents
Tonix Pharmaceuticals Holding Corp. Cash & Equivalents History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$207.6M
FY2025
5-year range
$24.9M / $207.6M
FY2023-FY2025
Trend
+110.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $25M to $208M over the past 2 years.
Based on SEC 10-K filings.
$208M in FY2025.
Improved from $25M to $208M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, cash & equivalents increased 110.2% year-over-year.
Company context
Key Data Points
- Altman Z-Score -0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $207.6M | +110.2% |
| FY2024 | $98.8M | +295.9% |
| FY2023 | $24.9M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 28, 2026